Pomalidomide-PEG4-COOH is primarily utilized in the development of targeted cancer therapies, particularly in the design of antibody-drug conjugates (ADCs). Its structure allows for the conjugation of pomalidomide, an immunomodulatory drug, to antibodies or other targeting molecules via the PEG4 linker. This enables precise delivery of the drug to cancer cells, minimizing off-target effects and enhancing therapeutic efficacy. The carboxyl group (-COOH) facilitates further chemical modifications, making it a versatile tool in drug development. Its application is especially significant in treating multiple myeloma and other hematologic malignancies, where targeted delivery is crucial for improving patient outcomes.